Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter

References

• Tan AC , AshleyDM , LopezGY , MalinzakM , FriedmanHS , KhasrawM. Management of glioblastoma: state of the art and future directions. CA Cancer J. Clin.70(4), 299–312 (2020).
   PubMed Web of Science ®Google Scholar
• Yabo YA , NiclouSP , GolebiewskaA. Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma. Neuro Oncol.24(5), 669–682 (2022).
   PubMed Web of Science ®Google Scholar
• Gupta T , TalukdarR , KannanS , DasguptaA , ChatterjeeA , PatilV. Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: updated systematic review and meta-analysis. Neurooncol. Pract.9(5), 354–363 (2022).
   PubMed Web of Science ®Google Scholar
• Rao V , KumarG , VibhavariRet al. Temozolomide resistance: a multifarious review on mechanisms beyond O-6-methylguanine-DNA methyltransferase. CNS Neurol. Disord. Drug Targets doi: https://doi.org/10.2174/1871527321666220404180944 (2022) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Di Nunno V , FranceschiE , TosoniAet al. Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Rev. Anticancer Ther.20(9), 785–795 (2020).
   PubMed Web of Science ®Google Scholar
• Tomar MS , KumarA , SrivastavaC , ShrivastavaA. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim. Biophys. Acta Rev. Cancer1876(2), 188616 (2021).
   PubMed Web of Science ®Google Scholar
• Cheng W , RenX , CaiJet al. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Oncotarget6(30), 29285–29295 (2015).
   PubMedGoogle Scholar
• Wang W , ZhangL , WangZet al. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. Oncotarget7(43), 69991–69999 (2016).
   PubMedGoogle Scholar
• Brandner S , McAleenanA , KellyCet al. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a cochrane systematic review. Neuro Oncol.23(9), 1457–1469 (2021).
   PubMed Web of Science ®Google Scholar
• Fan W , WangD , LiGet al. A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma. CNS Neurosci. Ther.28(12), 2090–2103 (2022).
   PubMed Web of Science ®Google Scholar
• Chen B , ZhouX , YangLet al. Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment. CNS Neurosci. Ther.28(12), 2148–2162 (2022).
   PubMed Web of Science ®Google Scholar
• Yu H , ZhangD , LianM. Identification of an epigenetic prognostic signature for patients with lower-grade gliomas. CNS Neurosci. Ther.27(4), 470–483 (2021).
   PubMed Web of Science ®Google Scholar
• Ahmadpour S , TaghaviT , SheidaA , TamehriZS , HamblinMR , MirzaeiH. Effects of microRNAs and long non-coding RNAs on chemotherapy response in glioma. Epigenomics14(9), 549–563 (2022).
   PubMed Web of Science ®Google Scholar
• Issa JP . DNA methylation as a clinical marker in oncology. J. Clin. Oncol.30(20), 2566–2568 (2012).
   PubMed Web of Science ®Google Scholar
• Galbraith K , SnuderlM. DNA methylation as a diagnostic tool. Acta Neuropathol. Commun.10(1), 71 (2022).
   PubMed Web of Science ®Google Scholar
• Yin A , ShangZ , EtcheverryAet al. Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas. Oncoimmunology10(1), 1902071 (2021).
   PubMed Web of Science ®Google Scholar
• Yin AA , LuN , EtcheverryAet al. A novel prognostic six-CpG signature in glioblastomas. CNS Neurosci. Ther.24(3), 167–177 (2018).
   PubMed Web of Science ®Google Scholar
• Li B , WangJ , LiuFet al. A novel pseudogene methylation signature to predict temozolomide outcome in non-G-CIMP glioblastomas. J. Oncol.2022, 6345160 (2022).
   PubMed Web of Science ®Google Scholar
• Malta TM , DeSouza CF , SabedotTSet al. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro Oncol.20(5), 608–620 (2018).
   PubMed Web of Science ®Google Scholar
• Noushmehr H , WeisenbergerDJ , DiefesKet al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell17(5), 510–522 (2010).
   PubMed Web of Science ®Google Scholar
• Bady P , SciuscioD , DiserensACet al. MGMT methylation analysis of glioblastoma on the Infinium methylation beadchip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol.124(4), 547–560 (2012).
   PubMed Web of Science ®Google Scholar
• Wiestler B , ClausR , HartliebSAet al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol.15(8), 1017–1026 (2013).
   PubMed Web of Science ®Google Scholar
• Brennan CW , VerhaakRG , McKennaAet al. The somatic genomic landscape of glioblastoma. Cell155(2), 462–477 (2013).
   PubMed Web of Science ®Google Scholar
• Etcheverry A , AubryM , DeTayrac Met al. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics11, 701 (2010).
   PubMed Web of Science ®Google Scholar
• Lai RK , ChenY , GuanXet al. Genome-wide methylation analyses in glioblastoma multiforme. PLOS ONE9(2), e89376 (2014).
   PubMed Web of Science ®Google Scholar
• Kurscheid S , BadyP , SciuscioDet al. Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biol.16, 16 (2015).
   PubMed Web of Science ®Google Scholar
• Horvath S , GaragnaniP , BacaliniMGet al. Accelerated epigenetic aging in Down syndrome. Aging Cell14(3), 491–495 (2015).
   PubMed Web of Science ®Google Scholar
• Du P , ZhangX , HuangCCet al. Comparison of beta-value and m-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics11, 587 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson WE , LiC , RabinovicA. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics8(1), 118–127 (2007).
   PubMed Web of Science ®Google Scholar
• Reich M , LiefeldT , GouldJ , LernerJ , TamayoP , MesirovJP. Genepattern 2.0. Nat. Genet.38(5), 500–501 (2006).
   PubMed Web of Science ®Google Scholar
• Barbie DA , TamayoP , BoehmJSet al. Systematic RNA interference reveals that oncogenic kRAS-driven cancers require TBK1. Nature462(7269), 108–112 (2009).
   PubMed Web of Science ®Google Scholar
• Subramanian A , TamayoP , MoothaVKet al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA102(43), 15545–15550 (2005).
   PubMed Web of Science ®Google Scholar
• Gould J , GetzG , MontiS , ReichM , MesirovJP. Comparative gene marker selection suite. Bioinformatics22(15), 1924–1925 (2006).
   PubMed Web of Science ®Google Scholar
• Charoentong P , FinotelloF , AngelovaMet al. Pan-cancer immunogenomic analyses reveal genotype–immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep.18(1), 248–262 (2017).
   PubMed Web of Science ®Google Scholar
• Wu B , MiaoY , BaiYet al. Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLOS ONE7(4), e34588 (2012).
   PubMed Web of Science ®Google Scholar
• Chen J , TongX , HanMet al. Cost–effectiveness of short-course radiation plus temozolomide for the treatment of newly diagnosed glioblastoma among elderly patients in China and the United States. Front. Pharmacol.12, 743979 (2021).
   PubMed Web of Science ®Google Scholar
• Loong HH , WongC , LeungLet al. Cost–effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. Cost Eff. Resour. Alloc.18, 2 (2020).
   PubMed Web of Science ®Google Scholar
• Hegi ME , DiserensAC , GorliaTet al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Yin AA , ZhangLH , ChengJXet al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. PLOS ONE8(9), e74242 (2013).
   PubMed Web of Science ®Google Scholar
• Yin AA , ZhangLH , ChengJXet al. The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis. PLOS ONE9(1), e85102 (2014).
   PubMed Web of Science ®Google Scholar
• Yin A , EtcheverryA , HeYet al. Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas. Oncotarget8(52), 89607–89619 (2017).
   PubMedGoogle Scholar
• Roessler J , AmmerpohlO , GutweinJet al. Quantitative cross-validation and content analysis of the 450 k DNA methylation array from Illumina, Inc. BMC Res. Notes5, 210 (2012).
   PubMedGoogle Scholar
• Yin AA , HeYL , EtcheverryAet al. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Clin. Epigenetics11(1), 76 (2019).
   PubMedGoogle Scholar